DEC1 deficiency promotes osteoclastic activity by augmenting NFATc1 signaling via transactivation and the Ca2+/calcineurin pathway
Biochemical Pharmacology · 2025
DOI: 10.1016/j.bcp.2025.116754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025. Verfasst von Haobin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Nanjing Medical University, Nanjing 211166, PR China. Hauptthemen laut MEDLINE: NFATC Transcription Factors, Calcineurin, Osteoclasts, Transcriptional Activation. Die Arbeit nennt 49 Literaturangaben. Gefördert von: NIAID NIH HHS, NICHD NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
We have previously demonstrated that DEC1 promotes osteoblast differentiation. This study aims to evaluate the impact of DEC1 knockout on osteopenic activities, such as osteoclast differentiation and the expression of bone-degrading genes. To gain mechanistic insights, we employed both in vivo and in vitro experiments, utilizing cellular and molecular approaches, including osteoclast differentiation assays and RNA-seq in combination with ChIP-seq. Our results showed that NFATc1, a master regulator of osteoclast differentiation, and PPP3CB, a member of the calcineurin family, were significantly upregulated in DEC1-/- mice. In vitro experiments revealed that osteoclast differentiation significantly increased both the number and size of osteoclasts in DEC1-/- bone marrow macrophages (BMMs) compared to DEC1+/+ BMMs. Additionally, NFATc1 expression was notably higher in DEC1-/- BMMs than in DEC1+/+ BMMs. Overexpression of DEC1 reduced NFATc1 promoter activity, while knockout increased it. Furthermore, intracellular free Ca2+ levels and calcineurin activity were elevated (∼150 %) in DEC1-/- BMMs compared to DEC1+/+ BMMs. Importantly, the use of calcineurin inhibitors and calcium channel blockers effectively abolished the increased osteoclast differentiation observed in DEC1-/- BMMs. In summary, DEC1 deficiency promotes osteoclast differentiation by enhancing NFATc1 signaling through transcriptional regulation and the Ca2+/calcineurin pathway. Clinically, the mRNA levels of DEC1 were reduced by up to 75 % in patients with osteoporosis. The findings of this study establish that inducing DEC1 expression, alongside attenuators of the Ca2+/calcineurin pathway, offers a molecular basis for preventing and treating osteoporosis associated with DEC1 deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Nanjing Medical University, Nanjing 211166, PR China.
- James L. Winkle College of Pharmacy University of Cincinnati, Cincinnati, OH 45229, USA.
- Nanjing Pukou District Traditional Chinese Medicine Hospital, Nanjing 210000, PR China.
- Department of Pharmacology, Nanjing Medical University, Nanjing 211166, PR China. Electronic address: jianyang@njmu.edu.cn.
Förderung
- NIAID NIH HHS
- NICHD NIH HHS
- National Institutes of Health
- National Natural Science Foundation of China
- Nanjing Medical University
Zitieren
APA
Wang, H., Guan, Y., Lin, L., Qiang, Z., Huo, Y., Zhu, L., Yan, B., Shao, S., Liu, W., & Yang, J. (2025). DEC1 deficiency promotes osteoclastic activity by augmenting NFATc1 signaling via transactivation and the Ca2+/calcineurin pathway. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2025.116754
Vancouver
Wang H, Guan Y, Lin L, Qiang Z, Huo Y, Zhu L, et al. DEC1 deficiency promotes osteoclastic activity by augmenting NFATc1 signaling via transactivation and the Ca2+/calcineurin pathway. Biochemical Pharmacology. 2025. doi:10.1016/j.bcp.2025.116754
BibTeX
@article{Wang2025,
author = {Wang, Haobin and Guan, Yu and Lin, Lan and Qiang, Zhiyi and Huo, Ying and Zhu, Ling and Yan, Bingfang and Shao, Shulin and Liu, Wei and Yang, Jian},
title = {DEC1 deficiency promotes osteoclastic activity by augmenting NFATc1 signaling via transactivation and the Ca2+/calcineurin pathway},
journal = {Biochemical Pharmacology},
year = {2025},
doi = {10.1016/j.bcp.2025.116754}
}
EUVIMED